Personalized Medicine events

May 2013
Munich, Germany

  • EuroBioForum 2013
    This edition of EuroBioForum was held in Munich, Germany May 27-28, 2013 and explored the potential areas for transnational and transregional collaboration in personalized medicine. The Annual Meeting served as a forum for exchanging views on the state of affairs in policy development and deployment, and on the challenges with respect to policies, implementation strategies and required investments. The Conference objectives are to provide insights into current policies, funding mechanisms and research agendas in personalized medicines. Representatives of national and regional governments, bioclusters, regional development agencies, funding agencies, national research councils, learned societies and industrial federations, have attended the meeting. A strong Canadian contribution has been provided through the national perspective presented by CIHR and Genome Canada, and through the regional perspectives of Genome BC, Genome Québec and the Ontario Genomics Institute.

February 2013
Toronto, ON

October 2012
Montreal, QC

September 2012
Montreal, QC

  • Canada-China Workshop on Genomics and Personalized Health
    In partnership with the National Natural Science Foundation of China (NSFC) and eight of the 13 CIHR Institutes (CIHR-ICR, CIHR-IG, CIHR-IA, CIHR-III, CIHR-ICRH, CIHR-IMHA, CIHR-INMD, and CIHR-INMHA).

May 2012
Niagara-on-the-Lake, ON

  • Rare Diseases Workshop
    In partnership with CIHR-IG and the British High Commission in Canada.

May 2012
Montreal, QC

January 2012
Ottawa, ON

  • Personalized Medicine in Canada: A Multi-Stakeholder Workshop to Examine the Canadian Perspective
    In partnership with Health Canada and three CIHR Institutes (CIHR-IG, CIHR-ICR, and CIHR-IHSPR), with grateful support from the Institute of Health Economics and CADTH.
  • Café Scientifique: “The Rare Disease Next Door: A Personalized Approach”
    When you consider the cumulative impact of the thousands of rare diseases, they add up to one big health care challenge. Advances in various technologies are offering hope to many patients, and many research findings are being translated into a personalized approach to medicine. The discussion focussed on the unique treatment needs of people with rare diseases, along with the need for Canada to develop legislation that will allow these individuals to have access to those treatments.

December 2011

  • Bioinformatics and Computational Biology Workshop
    In partnership with Genome Canada, CIHR-IG and CIHR-ICR.

October 2011
Montreal, QC

  • Innovations in Cancer Research
    Ten health and science reporters joined nine leading cancer researchers and clinician as they discussed the latest developments in cancer research. The overall theme of the day was to learn how cancer research drives innovations, which leads to better diagnosis, prevention, and personalized treatments, and ultimately better care and survivorship.

September 2011
Luxembourg and Qatar

  • Personalized Medicine: Metabolic Disruption and Disease
    In partnership with CIHR-ICR, CIHR-IG, CIHR-III, CIHR-INMD, Luxembourg, and Qatar.

June 2011
Ottawa, ON

  • Integrating the Physical and Applied Sciences into Health Research
    In partnership with CIHR-IG and CIHR-ICR.

June 2011
London, UK

  • Imaging Workshop
    In partnership with CIHR-ICR, Cancer Research UK (CRUK), and National Cancer Institute (NCI) of the US National Institutes of Health (NIH)

May 2011
Montreal, QC

  • CIHR Personalized Medicine Planning Meeting
    In partnership with CIHR-IG, CIHR-ICR, CIHR-IHSPR, CIHR-IPPH, CIHR-ICRH and CIHR-III.

March 2011
Ottawa, ON

  • Canadian Data Harmonization Roundtable

February 2011
Montreal, QC

  • Café Scientifique: "Personalized Cancer Medicine: One Size Does Not Fit All"
    More than 65 participants, including cancer patients and cancer survivors, gathered together to discuss the future of personalized cancer medicine with leading cancer researchers and clinicians. The participants heard how personalized medicine is influencing cancer patients today and how it is expected to affect them in the future.